Should domperidone for infants be dosed at 0.25 mg per kilogram per dose rather than per day?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Domperidone Dosing in Infants: Per Dose, Not Per Day

Domperidone for infants should be dosed at 0.25 mg/kg per dose, not per day, based on the most relevant pediatric evidence available.

Dosing Clarification

The 0.25 mg/kg figure represents a per-dose amount that is typically administered multiple times daily. 1 This is consistent with standard pediatric dosing practices where:

  • Typical dosing regimen: 0.25 mg/kg per dose, given 3-4 times daily
  • Total daily dose range: Approximately 0.8-1.8 mg/kg/day when administered at appropriate intervals 2, 3
  • Maximum daily dose: Should not exceed 30 mg total per day per current safety restrictions 4

Evidence-Based Dosing in Infants

Published pediatric studies demonstrate the following dosing patterns:

  • Neonatal studies: 0.3 mg/kg per dose administered at 8-hour intervals (total 0.9 mg/kg/day) 3
  • Infant studies: Average doses of 0.8 mg/kg/day divided into multiple doses 2
  • Higher reported doses: Up to 1.3-1.8 mg/kg/day in some neonatal populations, though these higher doses were associated with QTc prolongation concerns 2

Critical Safety Considerations

Cardiac monitoring is essential when using domperidone in infants:

  • QTc interval prolongation has been documented in infants receiving domperidone, particularly at doses ≥1.3 mg/kg/day 2
  • ECG monitoring should be performed before initiation and during treatment 2
  • Two studies reported QTc prolongation >450 ms in premature infants and neonates receiving 1.0-1.3 mg/kg/day 2

Important Caveats

Domperidone is not FDA-approved for use in humans in the United States 5, and its use in infants is entirely off-label. The drug carries significant restrictions in other jurisdictions:

  • European Medicines Agency limits use to patients ≤60 years, ≤30 mg/day, and ≤7 days duration 4, 6
  • These restrictions do not align well with typical pediatric gastroparesis management, which often requires longer treatment 6

Efficacy concerns exist: A randomized controlled trial in children aged 1-6 years with gastroenteritis found domperidone (0.5 mg/kg single dose) was not effective compared to placebo 7. Additionally, one neonatal study paradoxically showed an increase in gastroesophageal reflux episodes with domperidone 0.3 mg/kg per dose 3.

Practical Dosing Algorithm

When domperidone is deemed necessary despite off-label status:

  1. Starting dose: 0.25 mg/kg per dose, administered 3-4 times daily
  2. Baseline ECG: Obtain before initiating therapy 2
  3. Monitor: Repeat ECG after dose stabilization and with any dose increases
  4. Maximum: Keep total daily dose <1.0 mg/kg/day to minimize cardiac risk 2
  5. Discontinue: If QTc >450 ms (males) or >470 ms (females) develops 8

The distinction between per-dose and per-day dosing is clinically critical—confusing these could result in either subtherapeutic dosing or dangerous overdosing with cardiac complications.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Proarrhythmic effects of domperidone in infants: a systematic review].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2014

Research

Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring.

Journal of perinatology : official journal of the California Perinatal Association, 2008

Research

Cardiac safety and clinical efficacy of high-dose domperidone for long-term treatment of gastroparesis symptoms.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.